NEW YORK, April 30, 2019 /PRNewswire/ — Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological...
NEW YORK, NEW YORK October 16, 2017 /PR Newswire/Hoth Therapeutics Inc., a Nevada corporation (“Hoth” or the “Company”), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic...
NEW YORK, NEW YORK September 5, 2017 /PR Newswire/ Hoth Therapeutics Inc., a Nevada corporation (“Hoth” or the “Company”), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic...
Spherix Incorporated Acquires 6,800,000 shares of Hoth Therapeutics New York, NY July 3, 2017 /PR Newswire/ Spherix Incorporated (NASDAQ: SPEX) reportedtoday, following the disclosure made June 20th 2017, that the Company has closed the transaction with Hoth...
New York, NY, June 28, 2017 /PRNewswire/ Spherix Incorporated (NASDAQ: SPEX) an intellectual property development company committed to the fostering of technology and monetization of intellectual property, today issued a letter to shareholders. Dear Spherix...
Hoth’s BioLexa platform uses its proprietary technology to treat eczema without the use of traditional topical steroids. New York, NY June 20, 2017 / PRNewswire/ Spherix Incorporated (NASDAQ: SPEX) announced today that the Company has negotiated definitive terms to...
